BioMarin Pharmaceutical reported $819.04M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 5.69B 6B Sep/2026
Bayer EUR 9.92B 121M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Insmed USD 606.26M 79.46M Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
Moderna USD 1.18B 223M Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.92B 941M Jun/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026